Nick Leschly (Credit: Jeff Rumans at Endpoints News JPM20)

Blue­bird hits the brakes on Lenti­Glo­bin stud­ies, Zyn­te­glo mar­ket­ing af­ter AML, myelodys­plas­tic syn­drome cas­es spur fresh safe­ty con­cerns

Blue­bird bio $BLUE has run in­to a fresh set of trou­bles for its gene ther­a­py Lenti­Glo­bin.

The biotech, which has seen its gene ther­a­py work mired at the FDA due to CMC is­sues, re­vealed Tues­day morn­ing it had sus­pend­ed work on its ear­ly-stage study as well as the Phase III sick­le cell tri­al for Lenti­Glo­bin in or­der to in­ves­ti­gate two more se­ri­ous side ef­fects among pa­tients in the pro­gram.

In ad­di­tion, blue­bird CEO Nick Leschly hit the brakes on mar­ket­ing Zyn­te­glo (betibeglo­gene au­totem­cel; beti-cel) in Eu­rope, where it’s ap­proved for be­ta tha­lassemia, be­cause it us­es the same BB305 lentivi­ral vec­tor used in the gene ther­a­py for sick­le cell dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.